Latest Breaking News On - சிறுநீரகம் சேவை - Page 1 : vimarsana.com

Share this article Share this article NEW YORK, April 15, 2021 /PRNewswire/ The US Food and Drug Administration (FDA) has approved Illuminare-1, a small molecule, myelin binding agent, for their Investigational New Drug Application (IND). Illuminare-1 is being developed as a surgical adjunct to improve the visualization and delineation of critical nerve structures intra-operatively in real time with the aim of avoiding serious, and potentially permanent, unintended nerve injury. The first-in human clinical trial will be conducted at Memorial Sloan Kettering Cancer Center (MSK), along with collaborators from Illuminare Biotechnologies, in patients undergoing robot-assisted radical prostatectomy. Surgery plays a prominent role as first line treatment across many medical conditions. The ultimate goal of surgery is to repair or remove damaged and/or diseased tissue while preserving vital structures, including nerves. Even with advanced surgical techniques, unintended nerve injury re

Timothy donahueUrology serviceDrug administrationMemorial sloan kettering cancer centerInvestigational new drug applicationIlluminare biotechnologiesAssociate attending surgeonதீமோத்தேயு டொநேஹ்யூசிறுநீரகம் சேவைநினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம்